When Philadelphia quarterback Jalen Hurts stepped onto the field at Tottenham Hotspur Stadium on 11 October, he did so with a superficial blood clot already identified in his calf. Within days the clot migrated, leading to deep‑vein thrombosis and multiple pulmonary emboli, forcing him out for the rest of the season. The rapid progression of his condition and the decision to let him play have reignited debate over how the NFL safeguards player health, particularly during its expanding slate of international games.
Timeline of events
The sequence of medical assessments surrounding Hurts’ injury is well documented:
- Saturday, 10 October – After arriving in London, Hurts visited the Cleveland Clinic; an ultrasound revealed a superficial clot in his calf, yet he was cleared to play the next day.
- Sunday, 11 October – Hurts returned to his hotel around 3 a.m., played the full game against the Jacksonville Jaguars, and was cleared for the overnight flight home.
- Wednesday, 14 October – A follow‑up ultrasound showed the clot had moved, prompting his removal from the upcoming matchup.
- Monday, 19 October – A joint statement from the Eagles and Hurts’ agent confirmed a diagnosis of deep‑vein thrombosis and bilateral pulmonary emboli.
He is now on a blood‑thinning regimen and expected to recover, but the episode has already prompted a broader review of NFL medical practices.
Medical context and NFL protocols
Dr Allen Sills, the league’s chief medical officer, was present in London and coordinated Hurts’ evaluation at the Cleveland Clinic, an official NFL medical supplier for overseas games. While the NFL maintains detailed protocols for concussions, extreme heat, and emergency preparedness, Sills admitted that “the league does not have a protocol for situations such as this.” He added that the handling of Hurts’ case was “incredibly conservative” and expressed “complete confidence” in the Eagles’ approach.
Dr Niko Mihic, chief medical officer for Real Madrid and the medical coordinator for the upcoming Madrid game, noted that blood clots are “not that common” among athletes and emphasized the nuanced judgment required to decide whether a player can safely travel after a clot is identified. He warned that the “worst risk factor for recurrent embolisms is having had one previously,” underscoring the long‑term health implications for Hurts.
Player‑union response
The NFL Players Association (NFLPA) quickly called for a full investigation, stating that the league had previously indicated it would not review the care Hurts received. After negotiations, the NFL and NFLPA released a joint statement confirming they are “working together to review the matter.” The union’s involvement reflects growing concern that the league’s rapid expansion of international fixtures may outpace its medical safeguards.
Implications for the NFL’s international schedule
With a record nine international games slated for the 2024 season and ambitions for up to 16, the league faces heightened scrutiny. Upcoming matches in Madrid (8 November) and earlier games in Australia and Brazil have already raised questions about travel fatigue, field quality, and medical support. The Hurts case may prompt the NFL to develop specific guidelines for clot‑related injuries, including criteria for flight clearance and post‑game monitoring.
What this means for the Eagles
Philadelphia now lacks an experienced backup quarterback; Tanner McKee, the designated reserve, could not stop a 38‑21 loss to the Dallas Cowboys, extending the team’s losing streak under coach Nick Sirianni. With the trade deadline looming, the Eagles may need to consider roster moves or a longer‑term rebuild if Hurts’ health issues persist.
Looking ahead
Hurts’ situation illustrates a broader tension between the NFL’s growth ambitions and the imperative to protect player welfare. As the league finalizes medical preparations for future overseas games, it will need to balance logistical demands with robust, sport‑specific health protocols. The outcome of the joint NFL‑NFLPA review will likely set a precedent for how similar cases are handled, influencing both on‑field decisions and the league’s reputation among players and fans alike.